Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation ...

BEAM-101, a gene-editing stem cell therapy, showed early signs of efficacy among the first treated sickle cell patients in a ...

It's been two years since Destiny Hannah received a bone marrow transplant to reverse her sickle cell disease. Once a patient ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

ST. LOUIS — All morning, nurses had been coming in, taking vitals, offering blankets, pressing buttons to silence alarms. It ...

Sickle Cell Disease Market Size Was Valued at USD 2.40 Billion in 2023, and is Projected to Reach USD 12.38 Billion by 2032, ...

Beam Therapeutics' early clinical data shows promising results for sickle cell disease treatment using CRISPR gene editing tool. One patient died ...

THE United States has reaffirmed its commitment to supporting Tanzania in the fight against sickle cell disease with focus on ...

Participants at the launch of National Sickle Cell Disease Strategy and National Vaccine Policy The Ministry Of Health has ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the treatment of patients aged 12 years and older with (1) ...

A next generation Snap Cartridge, part of the Gazelle™ S-10B Hb Variant Test Multipack, will simplify sample preparation so ...